. Author manuscript; available in PMC: 2011 Jun 1.

Published in final edited form as: Infect Dis Clin North Am. 2010 Jun;24(2):439–459. doi: 10.1016/j.idc.2010.01.002

Table 1. Major prospective randomized controlled trials of invasive candidiasis.

Author, Year	Comparators	Number Enrolled^*	Proportion Candidemic (%)	C. albicans Infections (%)	End of Therapy Success (%)	Significance (P value)	Comments
Rex 1994 [122]	Fluconazole	113	100	70	72	0.17	Non-neutropenic population; Less toxicity with fluconazole.
Rex 1994 [122]	Amphotericin B	111	100	63	80	0.17	Non-neutropenic population; Less toxicity with fluconazole.
Rex 2003[123]	Fluconazole plus Placebo	107	100	68	56	0.043	Higher APACHE II scores in fluconazole arm; Mortality not improved with combination; Higher nephrotoxicity with combination.
Rex 2003[123]	Fluconazole plus Amphotericin B	112	100	68	69	0.043
Kullberg 2005[124]	Voriconazole	248	100	43	70	0.42	Non-blinded, non-neutropenic population; More renal toxicity & SAEs with AmB.
Kullberg 2005[124]	Amphotericin B followed by Fluconazole	122	100	51	74	0.42
Mora-Duarte 2002[125]	Caspofungin	109	83	36	73	0.09	No difference in mortality; More drug related adverse events with AmB.
Mora-Duarte 2002[125]	Amphotericin B	115	79	54	62	0.09
Kuse 2007[126]	Micafungin	264	83	39	74	NS	12% of study population neutropenic
Kuse 2007[126]	LAMB	267	84	43	70	NS	12% of study population neutropenic
Reboli 2007[127]	Anidulafungin	127	91	64	76	NS	3% of study population neutropenic; Microbiologic response higher with anidulafungin.
Reboli 2007[127]	Fluconazole	118	87	59	60	NS
Pappas 2007[128]	Caspofungin	188	86	44	72	NS	9% of study population neutropenic
	Micafungin 100mg	191	85	48	76
	Micafungin 150 mg	199	84	51	71

NS, not significant; LAMB, liposomal amphotericin B; AmB, amphotericin B; SAEs, serious adverse events

Modified intent to treat population